AR and prostate carcinoma: TLE5 directly interacts with AR and prevents AR from binding DNA, thus suppressing ligand-dependent AR target gene expression and inhibiting prostate cancer progression and metastasis (Yu et al., 2001; Zhang et al., 2010; Okada et al., 2017) (Figure 5).